Telomir Pharmaceuticals Inc. has announced favorable results from a series of Good Laboratory Practice $(GLP)$ toxicology and safety pharmacology studies for its lead therapeutic candidate, Telomir-1 (Zn-Telomir). The studies, conducted in both in vitro systems and in vivo rat and dog models, found that Telomir-1 was generally well tolerated, with no treatment-related or dose-limiting toxicities observed. The company reported no adverse effects on cardiovascular, respiratory, or phototoxicity parameters, and any observed findings were limited, reversible, and considered non-adverse. Telomir Pharmaceuticals is preparing for the submission of an Investigational New Drug $(IND)$ application in the first quarter of 2026 and anticipates beginning first-in-human clinical studies in the first half of 2026. The company is also planning to submit scientific manuscripts for publication and to present data at multiple oncology-focused scientific conferences in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-028126), on December 17, 2025, and is solely responsible for the information contained therein.
Comments